4.6 Article

OX40 Drives Protective Vaccinia Virus-Specific CD8 T Cells

Journal

JOURNAL OF IMMUNOLOGY
Volume 181, Issue 11, Pages 7969-7976

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.181.11.7969

Keywords

-

Categories

Funding

  1. National Institutes of Health [CA91837, AI67341, AI77079, AI56268, HHSN266200400124C, AI63107]
  2. Pew Scholar Award

Ask authors/readers for more resources

Vaccinia virus (VACV) affords long-lasting protection against variola virus, the agent of smallpox. VACV-reactive CD8 T cells contribute to protection but their molecular control is unknown. We show that the TNFR molecule OX40 (CD134) controls primary VACV-specific CD8 T cell expansion and antiviral cytokine production and dictates development of strong memory to both dominant and subdominant VACV epitopes. Using adoptive transfer of OX40-deficient CD8 TCR-transgenic T cells responding to Ag in the context of VACV infection, we round that this reflects a direct action of OX40 expressed by CD8 T cells. Furthermore, CD8 T cells that can protect against lethal VACV challenge do not develop in mice deficient in OX40. Thus, OX40, which has been found to play little if any role in the generation of CD8 T cells to several viruses, including lymphocytic choriomeningitis virus and influenza, plays a dominant role in shaping the CD8 T cell response to VACV. These data suggest that unique costimulatory pathways might control alternate antiviral CD8 responses, demonstrating the plasticity of the immune response in utilizing different mechanisms to achieve similar ultimate goals. The Journal of Immunology, 2008, 181: 7969-7976.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available